drugset / Trial / NCT04867941

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

NCT04867941

Phase 1 Completed 18 enrolled Acerta Pharma BV
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will evaluate the influence of hepatic insufficiency on the PK of ACP-196.

Timeline

Start
2014-10-21
Primary completion
2015-02-02
Completion
2015-02-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule 50 mg Oral

Indications